Stock Analysis on Net

Analysis of Short-term (Operating) Activity Ratios 
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Pfizer Inc., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Turnover Ratios
Inventory turnover 1.57 1.51 1.46 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67
Receivables turnover 5.03 5.27 4.40 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99
Payables turnover 3.72 3.07 3.32 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66
Working capital turnover 7.47 10.58 6.08 10.68 6.64 8.64 5,036.00 29.17 1.62 2.03 6.89 11.00 3.83 5.05 6.10
Average No. Days
Average inventory processing period 232 242 251 239 229 222 219 178 170 149 138 158 119 95 101 100 99
Add: Average receivable collection period 73 69 83 69 69 66 87 74 72 69 58 48 48 40 59 55 52
Operating cycle 305 311 334 308 298 288 306 252 242 218 196 206 167 135 160 155 151
Less: Average payables payment period 98 119 110 106 110 115 99 79 87 98 72 93 76 72 66 59 55
Cash conversion cycle 207 192 224 202 188 173 207 173 155 120 124 113 91 63 94 96 96

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


The analysis of short-term operating activity indicates a systemic deceleration in efficiency across the primary components of the operating cycle. There is a pronounced trend toward slower asset turnover and an extended cash conversion cycle, suggesting a significant shift in the operational rhythm and liquidity management over the observed period.

Inventory Management
A substantial decline in inventory turnover is observed, falling from 3.67 in April 2022 to 1.57 by March 2026. This contraction is mirrored by the average inventory processing period, which expanded from 99 days to 232 days. The data reveals a steady increase in the time required to move goods through the system, indicating potential challenges in demand forecasting, an accumulation of unsold stock, or a strategic buildup of inventory.
Receivables and Collection Efficiency
Receivables turnover exhibits a general downward trajectory, decreasing from 6.99 to 5.03. Consequently, the average receivable collection period has extended from 52 days to 73 days. Although there were periodic fluctuations—most notably a peak in collection time of 87 days in September 2024—the overall trend points to a deterioration in the speed at which credit sales are converted into cash.
Payables and Supplier Relations
The payables turnover ratio decreased from 6.66 to 3.72, reflecting a corresponding increase in the average payables payment period from 55 days to 98 days. The extension of payment terms suggests a strategic effort to preserve cash flow, potentially acting as a buffer to mitigate the liquidity pressures created by the slowing inventory and receivables cycles.
Operating and Cash Conversion Cycles
The cumulative effect of slowing inventory and receivables movements has resulted in a dramatic expansion of the operating cycle, which grew from 151 days in April 2022 to 305 days by March 2026. While the extended payables period partially offsets this, the cash conversion cycle still experienced a significant increase, rising from 96 days to 207 days. This indicates that a substantially larger amount of capital is tied up in operating activities for a longer duration.
Working Capital Productivity
Working capital turnover demonstrates extreme volatility, with values fluctuating significantly. A notable anomaly occurs in September 2024, where the ratio reaches an outlier value of 5,036.00, suggesting a period of extreme compression in net working capital. Aside from this irregularity, the ratio does not show a stable trend, reflecting inconsistency in how effectively working capital is utilized to generate revenue.

AI Ask an analyst for more


Turnover Ratios


Average No. Days


Inventory Turnover

Pfizer Inc., inventory turnover calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cost of sales 3,548 5,272 4,172 3,778 2,845 5,909 5,263 3,300 3,379 7,562 9,269 3,237 4,886 9,649 6,063 8,648 9,984
Inventories 10,667 10,654 11,468 11,669 10,852 10,851 11,721 11,447 10,892 10,189 10,204 10,310 9,541 8,981 9,513 10,454 9,979
Short-term Activity Ratio
Inventory turnover1 1.57 1.51 1.46 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.65 3.68 3.65 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96
Amgen Inc. 1.91 1.93 1.92 1.88 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48
Bristol-Myers Squibb Co. 5.20 5.18 5.31 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55
Danaher Corp. 3.90 4.04 3.67 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87
Eli Lilly & Co. 0.85 0.80 0.83 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93
Gilead Sciences Inc. 3.21 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Johnson & Johnson 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Merck & Co. Inc. 2.65 2.46 2.27 2.25 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74
Regeneron Pharmaceuticals Inc. 0.74 0.66 0.64 0.64 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27
Thermo Fisher Scientific Inc. 4.87 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Vertex Pharmaceuticals Inc. 0.95 0.98 0.99 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Inventory turnover = (Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025 + Cost of salesQ2 2025) ÷ Inventories
= (3,548 + 5,272 + 4,172 + 3,778) ÷ 10,667 = 1.57

2 Click competitor name to see calculations.


A comprehensive analysis of the operating activity ratios reveals a significant and sustained decline in inventory efficiency from April 2022 through March 2026. While inventory balances remained relatively stable with a slight upward bias, the cost of sales exhibited substantial volatility and a general downward trend, leading to a marked reduction in the inventory turnover ratio.

Inventory Turnover Trend
The inventory turnover ratio experienced a consistent downward trajectory, moving from a peak of 3.82 in December 2022 to a low of 1.46 in September 2025. This decline indicates that inventory is moving through the supply chain more slowly, suggesting a potential misalignment between stock levels and market demand or a strategic accumulation of reserves that has not been offset by proportional sales growth.
Cost of Sales Volatility
Expenditures related to the cost of sales showed extreme fluctuations throughout the period. High peaks were recorded in early 2022 and October 2023, followed by periods of sharp contraction, most notably in the first half of 2024. Because the cost of sales serves as the numerator in the turnover calculation, these contractions significantly pressured the ratio downward, especially when occurring alongside stable or rising inventory levels.
Inventory Level Analysis
Inventory balances demonstrated a gradual increase over the observed timeframe, rising from approximately 9.98 billion USD in April 2022 to a peak of 11.72 billion USD in September 2024. The lack of a corresponding reduction in inventory holdings during periods of lower sales volume contributed to the overall erosion of operational efficiency.
Recent Performance Stabilization
In the final quarters of the analysis, the inventory turnover ratio showed signs of stabilization and a marginal recovery, increasing from 1.46 in September 2025 to 1.57 by March 2026. This suggests a potential correction in inventory management strategies or a slight recovery in the rate of sales relative to existing stock levels.

AI Ask an analyst for more


Receivables Turnover

Pfizer Inc., receivables turnover calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Revenues 14,451 17,557 16,654 14,653 13,715 17,763 17,702 13,283 14,879 14,568 13,492 13,007 18,486 24,289 22,638 27,742 25,661
Trade accounts receivable, net of allowance for doubtful accounts 12,585 11,874 14,260 12,078 11,845 11,463 14,451 11,393 10,989 11,177 11,086 10,231 12,305 10,952 16,076 15,155 13,225
Short-term Activity Ratio
Receivables turnover1 5.03 5.27 4.40 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 5.03 4.86 4.67 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29
Amgen Inc. 3.88 3.67 4.06 3.85 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81
Danaher Corp. 6.49 6.28 6.46 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87
Eli Lilly & Co. 3.92 3.67 3.69 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64
Gilead Sciences Inc. 6.17 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Johnson & Johnson 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Merck & Co. Inc. 5.39 5.52 5.30 5.37 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49
Regeneron Pharmaceuticals Inc. 2.60 2.50 2.51 2.53 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41
Thermo Fisher Scientific Inc. 4.91 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Vertex Pharmaceuticals Inc. 6.12 5.85 6.02 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Receivables turnover = (RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025) ÷ Trade accounts receivable, net of allowance for doubtful accounts
= (14,451 + 17,557 + 16,654 + 14,653) ÷ 12,585 = 5.03

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a general downward trend in the efficiency of receivables collection over the observed period. While the receivables turnover ratio experienced a significant peak in late 2022, it has since declined and entered a period of relative stabilization at a lower level.

Initial Peak and Volatility (2022)
The receivables turnover ratio began at 6.99 in April 2022 and reached a peak of 9.16 by December 2022. This peak corresponds with a sharp reduction in trade accounts receivable, which fell from 16,076 million USD in October 2022 to 10,952 million USD in December 2022, suggesting a period of highly accelerated collections or a significant write-down of receivables during the final quarter of that year.
Period of Decline (2023 - mid-2024)
Following the 2022 peak, a consistent deterioration in the turnover ratio is observed. The ratio fell from 7.57 in April 2023 to a low of 4.18 by September 2024. This decline occurred alongside a general reduction in quarterly revenues, moving from highs of over 25,000 million USD in early 2022 to a range between 13,000 million USD and 18,000 million USD. The downward trend indicates that the company is collecting its receivables more slowly relative to its sales volume.
Stabilization Phase (Late 2024 - 2026)
From December 2024 through March 2026, the receivables turnover ratio exhibits a plateau, fluctuating within a narrow range between 4.40 and 5.55. The ratio ended the period at 5.03 in March 2026. This suggests that the collection cycle has reached a new equilibrium, although this equilibrium is significantly less efficient than the levels observed in 2022.

The correlation between declining revenues and a lower turnover ratio suggests a potential shift in credit terms or a change in the customer payment profile. The transition from a peak ratio of 9.16 to a concluding ratio of 5.03 represents a substantial increase in the average time required to convert trade receivables into cash.

AI Ask an analyst for more


Payables Turnover

Pfizer Inc., payables turnover calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cost of sales 3,548 5,272 4,172 3,778 2,845 5,909 5,263 3,300 3,379 7,562 9,269 3,237 4,886 9,649 6,063 8,648 9,984
Trade accounts payable 4,506 5,240 5,024 5,166 5,240 5,633 5,314 5,106 5,591 6,710 5,338 6,081 6,123 6,809 6,267 6,208 5,506
Short-term Activity Ratio
Payables turnover1 3.72 3.07 3.32 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 4.02 5.09 4.29 4.12 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65
Bristol-Myers Squibb Co. 3.38 3.90 3.42 2.61 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25
Danaher Corp. 5.68 5.45 5.78 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04
Eli Lilly & Co. 2.47 2.05 2.37 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24
Gilead Sciences Inc. 9.52 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Johnson & Johnson 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Merck & Co. Inc. 4.44 3.72 3.53 3.82 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25
Regeneron Pharmaceuticals Inc. 2.24 2.24 2.30 2.83 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39
Thermo Fisher Scientific Inc. 8.00 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Vertex Pharmaceuticals Inc. 3.44 3.58 3.83 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Payables turnover = (Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025 + Cost of salesQ2 2025) ÷ Trade accounts payable
= (3,548 + 5,272 + 4,172 + 3,778) ÷ 4,506 = 3.72

2 Click competitor name to see calculations.


An analysis of the short-term operating activity indicates a significant long-term decline in the payables turnover ratio, reflecting a shift in the company's supplier payment cycle. The ratio transitioned from a peak of 6.66 in April 2022 to a more stabilized range between 3.07 and 4.60 during the 2024 and 2025 periods.

Payables Turnover Trajectory
A consistent downward trend in the turnover ratio is observable from early 2022 through the end of 2023, where the ratio fell from 6.66 to 3.72. Although minor fluctuations occurred in 2024 and 2025, the ratio remained substantially lower than the initial 2022 levels, reaching a low of 3.07 in December 2025 before recovering slightly to 3.72 by March 2026.
Correlation with Cost of Sales
The contraction in the turnover ratio is closely linked to a general reduction in the cost of sales. High cost of sales figures in 2022, peaking at 9,984 million USD, supported a higher turnover. As the cost of sales decreased—falling to levels between 2,845 million USD and 5,909 million USD in the 2024-2026 period—the turnover ratio declined accordingly, suggesting that the volume of purchases decreased more rapidly than the balances owed to suppliers.
Trade Accounts Payable Stability
Trade accounts payable remained relatively stable throughout the analyzed period, generally fluctuating between 4,506 million USD and 6,809 million USD. Because the payables balance did not decrease proportionally with the reduction in the cost of sales, the resulting turnover ratio declined, indicating an extension in the average time taken to settle obligations with suppliers.
Operational Cycle Insights
The shift from a turnover ratio of 6.66 to approximately 3.72 suggests a transition toward a slower payment cycle. This pattern indicates an increase in the company's ability to retain cash for longer periods by extending the payment duration to vendors, effectively leveraging trade credit to manage short-term liquidity as the scale of operations, measured by cost of sales, contracted.

AI Ask an analyst for more


Working Capital Turnover

Pfizer Inc., working capital turnover calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Current assets 42,822 42,898 46,924 43,703 45,861 50,358 43,223 37,825 42,415 43,333 74,012 73,347 50,078 51,259 70,403 67,466 54,420
Less: Current liabilities 34,348 36,984 36,596 37,726 36,452 42,995 43,211 43,819 40,497 47,794 31,136 34,647 36,562 42,138 44,314 47,410 39,268
Working capital 8,474 5,914 10,328 5,977 9,409 7,363 12 (5,994) 1,918 (4,461) 42,876 38,700 13,516 9,121 26,089 20,056 15,152
 
Revenues 14,451 17,557 16,654 14,653 13,715 17,763 17,702 13,283 14,879 14,568 13,492 13,007 18,486 24,289 22,638 27,742 25,661
Short-term Activity Ratio
Working capital turnover1 7.47 10.58 6.08 10.68 6.64 8.64 5,036.00 29.17 1.62 2.03 6.89 11.00 3.83 5.05 6.10
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc. 5.44 9.85 5.66 5.35 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34
Bristol-Myers Squibb Co. 5.84 7.83 6.20 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24
Danaher Corp. 3.83 4.13 7.39 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91
Eli Lilly & Co. 3.97 3.19 2.71 4.92 4.38 10.32 6.06 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19
Gilead Sciences Inc. 3.19 4.43 5.12 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68
Johnson & Johnson 66.14 62.88 24.63 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57
Merck & Co. Inc. 8.15 4.28 3.39 5.77 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09
Regeneron Pharmaceuticals Inc. 1.14 1.05 1.05 1.08 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46
Thermo Fisher Scientific Inc. 5.87 3.30 5.90 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13
Vertex Pharmaceuticals Inc. 1.56 1.64 1.92 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Working capital turnover = (RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025) ÷ Working capital
= (14,451 + 17,557 + 16,654 + 14,653) ÷ 8,474 = 7.47

2 Click competitor name to see calculations.


The analysis of working capital turnover reveals a period of extreme volatility followed by a trend toward operational stabilization. The fluctuations in the turnover ratio are primarily driven by drastic shifts in net working capital rather than consistent changes in revenue streams.

Revenue Trends
Revenues peaked in mid-2022 at approximately $27.7 billion and underwent a general decline, eventually stabilizing within a range of $13 billion to $18 billion between 2023 and 2026. This suggests that the volatility observed in the turnover ratio is a result of balance sheet management rather than sales instability.
Working Capital Volatility
Net working capital exhibited significant instability, reaching a peak of $42.8 billion in October 2023 before swinging to negative values in December 2023 (-$4.4 billion) and June 2024 (-$5.9 billion). These wide variances created inconsistent turnover metrics, reflecting periods of excessive liquidity followed by periods of negative net current assets.
Turnover Ratio Anomalies
The working capital turnover ratio experienced extreme mathematical spikes during 2024. A notable outlier occurred in September 2024, where the ratio reached 5,036.00. This was caused by working capital dropping to a nominal value of $12 million, which artificially inflated the ratio and does not reflect a sustainable increase in operational efficiency.
Stabilization and Normalization
From December 2024 through March 2026, the ratio transitioned into a more normalized pattern, fluctuating between 6.08 and 10.68. During this period, working capital remained positive and relatively stable, ranging between $5.9 billion and $10.3 billion, indicating a more consistent relationship between the company's short-term assets and its revenue generation capabilities.

AI Ask an analyst for more


Average Inventory Processing Period

Pfizer Inc., average inventory processing period calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Inventory turnover 1.57 1.51 1.46 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67
Short-term Activity Ratio (no. days)
Average inventory processing period1 232 242 251 239 229 222 219 178 170 149 138 158 119 95 101 100 99
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 100 99 100 107 98 90 89 75 75 73 77 85 81 75 66 73 74
Amgen Inc. 191 189 190 194 195 199 209 257 321 411 259 265 279 281 272 260 247
Bristol-Myers Squibb Co. 70 70 69 70 69 67 102 98 99 91 84 83 93 84 76 79 80
Danaher Corp. 94 90 99 101 96 88 101 102 98 96 104 102 104 91 96 98 94
Eli Lilly & Co. 428 454 441 435 379 329 349 316 312 298 261 267 268 237 196 204 189
Gilead Sciences Inc. 114 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Johnson & Johnson 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Merck & Co. Inc. 138 148 160 162 150 147 149 153 151 144 139 137 134 124 118 119 133
Regeneron Pharmaceuticals Inc. 491 556 571 570 582 572 573 562 553 519 508 532 549 562 440 379 287
Thermo Fisher Scientific Inc. 75 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Vertex Pharmaceuticals Inc. 384 373 369 345 320 287 267 238 222 214 213 192 177 156 136 135 129

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 1.57 = 232

2 Click competitor name to see calculations.


An analysis of the short-term operating activity ratios indicates a significant deterioration in inventory management efficiency from April 2022 through March 2026. The period is characterized by a consistent decline in the turnover rate and a corresponding substantial increase in the time required to process inventory.

Inventory Turnover Ratio
The inventory turnover ratio remained relatively stable during 2022, peaking at 3.82 in December 2022. However, starting in April 2023, a sustained downward trend is observed. The ratio declined from 3.07 in April 2023 to a low of 1.46 by September 2025. Although a slight recovery is noted in the final two quarters, ending at 1.57 in March 2026, the overall turnover capacity has decreased by more than 50% compared to the initial observation period.
Average Inventory Processing Period
The average inventory processing period exhibits an inverse correlation with the turnover ratio, showing a marked increase in the number of days inventory is held. For the majority of 2022, the processing period remained steady between 95 and 101 days. A sharp upward trajectory began in early 2023, with the period extending to 119 days in April and continuing to rise until it reached a peak of 251 days in September 2025. By March 2026, the period moderated slightly to 232 days, though it remains significantly higher than 2022 levels.

The convergence of these trends suggests a slowing of the operational cycle. The transition from a processing period of approximately 100 days to over 230 days indicates that inventory is remaining stationary for more than twice as long as in the previous period. This shift suggests potential challenges in demand forecasting, an accumulation of unsold stock, or a strategic shift in inventory stockpiling that has negatively impacted short-term liquidity and operational efficiency.

AI Ask an analyst for more


Average Receivable Collection Period

Pfizer Inc., average receivable collection period calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Receivables turnover 5.03 5.27 4.40 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99
Short-term Activity Ratio (no. days)
Average receivable collection period1 73 69 83 69 69 66 87 74 72 69 58 48 48 40 59 55 52
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 73 75 78 79 79 71 75 78 80 75 76 75 74 71 68 72 69
Amgen Inc. 94 99 90 95 91 77 86 86 88 99 88 84 84 82 79 79 76
Danaher Corp. 56 58 56 54 54 54 54 51 52 60 59 55 53 57 51 54 53
Eli Lilly & Co. 93 99 99 97 90 89 92 103 80 97 93 93 99 88 84 80 79
Gilead Sciences Inc. 59 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Johnson & Johnson 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Merck & Co. Inc. 68 66 69 68 62 58 66 68 68 63 64 69 66 58 59 62 66
Regeneron Pharmaceuticals Inc. 140 146 146 144 144 160 161 155 146 158 156 148 151 160 148 132 107
Thermo Fisher Scientific Inc. 74 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Vertex Pharmaceuticals Inc. 60 62 61 61 59 53 60 58 64 58 58 60 61 59 58 58 59

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.03 = 73

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a general deterioration in the efficiency of receivables management over the period from April 2022 through March 2026. A clear inverse correlation exists between the receivables turnover ratio and the average receivable collection period, with a long-term trend toward slower cash conversion from credit sales.

Receivables Turnover Trends
The receivables turnover ratio demonstrates a predominantly downward trajectory. Starting at 6.99 in April 2022, the ratio experienced a significant peak of 9.16 by December 31, 2022, before entering a period of steady decline. The ratio reached a low of 4.18 in September 2024, indicating a reduction in the frequency with which the company collects its average receivables balance. While some volatility is observed in the final year of the period, the ratio stabilized around the 5.03 to 5.27 range, remaining substantially lower than the levels observed in early 2022.
Average Receivable Collection Period Trends
The average collection period shows a corresponding upward trend, reflecting an increase in the time required to convert receivables into cash. The period began at 52 days in April 2022 and reached a minimum of 40 days in December 2022. Subsequently, the collection period grew consistently, peaking at 87 days in September 2024. Although a correction occurred in December 2024, bringing the period down to 66 days, the timeline remained elevated compared to the 2022 baseline, ending the analyzed period at 73 days in March 2026.
Operational Efficiency Observations
The data indicates a systemic slowing of the credit-to-cash cycle. The transition from an average collection period of approximately 52-59 days in 2022 to a range of 69-83 days in 2024 and 2025 suggests a shift in customer payment behavior or a change in the company's credit terms. The most acute decline in efficiency occurred between December 2023 and September 2024, where the collection period expanded from 69 days to 87 days, coinciding with the lowest recorded turnover ratios.

AI Ask an analyst for more


Operating Cycle

Pfizer Inc., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Average inventory processing period 232 242 251 239 229 222 219 178 170 149 138 158 119 95 101 100 99
Average receivable collection period 73 69 83 69 69 66 87 74 72 69 58 48 48 40 59 55 52
Short-term Activity Ratio
Operating cycle1 305 311 334 308 298 288 306 252 242 218 196 206 167 135 160 155 151
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 173 174 178 186 177 161 164 153 155 148 153 160 155 146 134 145 143
Amgen Inc. 285 288 280 289 286 276 295 343 409 510 347 349 363 363 351 339 323
Danaher Corp. 150 148 155 155 150 142 155 153 150 156 163 157 157 148 147 152 147
Eli Lilly & Co. 521 553 540 532 469 418 441 419 392 395 354 360 367 325 280 284 268
Gilead Sciences Inc. 173 166 170 169 159 156 160 172 164 163 169 163 159 162 137 136 132
Johnson & Johnson 239 238 246 240 228 226 236 233 222 218 211 232 220 209 196 198 192
Merck & Co. Inc. 206 214 229 230 212 205 215 221 219 207 203 206 200 182 177 181 199
Regeneron Pharmaceuticals Inc. 631 702 717 714 726 732 734 717 699 677 664 680 700 722 588 511 394
Thermo Fisher Scientific Inc. 149 148 156 153 148 142 150 144 142 142 146 146 145 145 148 157 164
Vertex Pharmaceuticals Inc. 444 435 430 406 379 340 327 296 286 272 271 252 238 215 194 193 188

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 232 + 73 = 305

2 Click competitor name to see calculations.


The operating cycle exhibits a significant and sustained expansion over the analyzed period, indicating a substantial increase in the time required to convert investment in inventory back into cash through sales and collections.

Average Inventory Processing Period
A pronounced upward trend is observed in the time required to process and sell inventory. From a baseline of 99 days in April 2022, the period remained relatively stable until early 2023, after which it accelerated sharply. The duration peaked at 251 days by September 2025, representing more than a twofold increase. Although a slight contraction occurred toward the end of the period, ending at 232 days in March 2026, the inventory processing time remains fundamentally elevated compared to 2022 levels.
Average Receivable Collection Period
The collection period demonstrates a general increase characterized by higher volatility than the inventory metric. After an initial decrease to 40 days in December 2022, the period entered a growth phase, reaching a peak of 87 days in September 2024. Subsequent quarters show fluctuations between 66 and 83 days, concluding at 73 days in March 2026. This indicates a general slowing in the efficiency of converting accounts receivable into cash.
Overall Operating Cycle
The cumulative effect of the extended inventory processing and slower receivable collections resulted in a dramatic lengthening of the total operating cycle. The cycle grew from 151 days in April 2022 to a maximum of 334 days in September 2025. While the cycle moderated slightly to 305 days by March 2026, the overall trajectory indicates a significant reduction in short-term operational liquidity and efficiency, as the time elapsed between the acquisition of raw materials and the collection of payment has more than doubled.

AI Ask an analyst for more


Average Payables Payment Period

Pfizer Inc., average payables payment period calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Payables turnover 3.72 3.07 3.32 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66
Short-term Activity Ratio (no. days)
Average payables payment period1 98 119 110 106 110 115 99 79 87 98 72 93 76 72 66 59 55
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 91 72 85 89 70 54 61 73 60 69 70 64 73 90 69 72 78
Bristol-Myers Squibb Co. 108 94 107 140 104 94 106 120 117 111 97 108 114 109 96 107 112
Danaher Corp. 64 67 63 65 66 66 60 63 62 65 65 63 64 67 65 73 72
Eli Lilly & Co. 148 178 154 161 140 140 135 142 127 134 130 138 119 106 86 87 70
Gilead Sciences Inc. 38 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Johnson & Johnson 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Merck & Co. Inc. 82 98 103 95 92 98 86 83 81 89 80 80 84 89 71 75 86
Regeneron Pharmaceuticals Inc. 163 163 158 129 129 146 94 110 137 122 106 116 136 138 98 91 68
Thermo Fisher Scientific Inc. 46 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Vertex Pharmaceuticals Inc. 106 102 95 102 105 98 98 85 96 106 117 115 107 103 44 73 66

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 3.72 = 98

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a sustained increase in the average payables payment period, indicating a significant extension in the timeframe required to settle obligations with suppliers.

Payables Turnover Trajectory
A consistent downward trend in payables turnover is observed, declining from 6.66 in April 2022 to a period low of 3.07 in December 2025. This contraction in the turnover ratio reflects a reduction in the frequency with which the organization clears its accounts payable, contributing to an overall slowing of the payment cycle.
Expansion of the Payment Period
The average payables payment period more than doubled over the analyzed timeframe, rising from 55 days in April 2022 to a peak of 119 days in December 2025. This expansion suggests a strategic shift toward retaining cash for longer durations, thereby increasing the available working capital by deferring outflows to vendors.
Volatility and Period Peaks
The data exhibits several phases of volatility. An initial climb reached 93 days by July 2023, followed by a sharp correction to 72 days in October 2023. A subsequent period of accelerated extension began in September 2024, with the payment period consistently exceeding 100 days through December 2025. A final correction is noted in March 2026, where the period decreased to 98 days.

AI Ask an analyst for more


Cash Conversion Cycle

Pfizer Inc., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Average inventory processing period 232 242 251 239 229 222 219 178 170 149 138 158 119 95 101 100 99
Average receivable collection period 73 69 83 69 69 66 87 74 72 69 58 48 48 40 59 55 52
Average payables payment period 98 119 110 106 110 115 99 79 87 98 72 93 76 72 66 59 55
Short-term Activity Ratio
Cash conversion cycle1 207 192 224 202 188 173 207 173 155 120 124 113 91 63 94 96 96
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. 194 216 195 200 216 222 234 270 349 441 277 285 290 273 282 267 245
Danaher Corp. 86 81 92 90 84 76 95 90 88 91 98 94 93 81 82 79 75
Eli Lilly & Co. 373 375 386 371 329 278 306 277 265 261 224 222 248 219 194 197 198
Gilead Sciences Inc. 135 124 122 135 116 107 111 143 130 132 132 123 118 104 104 105 100
Johnson & Johnson 116 93 127 121 105 89 116 112 109 86 100 99 100 72 78 82 80
Merck & Co. Inc. 124 116 126 135 120 107 129 138 138 118 123 126 116 93 106 106 113
Regeneron Pharmaceuticals Inc. 468 539 559 585 597 586 640 607 562 555 558 564 564 584 490 420 326
Thermo Fisher Scientific Inc. 103 98 112 110 104 97 112 107 105 101 111 112 106 97 111 116 118
Vertex Pharmaceuticals Inc. 338 333 335 304 274 242 229 211 190 166 154 137 131 112 150 120 122

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 232 + 7398 = 207

2 Click competitor name to see calculations.


The cash conversion cycle exhibits a pronounced expansion over the period from April 2022 through March 2026, indicating a significant slowdown in the efficiency of working capital management. While the cycle initially remained stable and experienced a temporary contraction toward the end of 2022, it subsequently entered a long-term upward trajectory, increasing from a trough of 63 days in December 2022 to a peak of 224 days in September 2025.

Average Inventory Processing Period
A sustained and aggressive increase is observed in the time required to process inventory. Starting from 99 days in April 2022, this metric grew steadily, crossing the 200-day threshold by September 2024 and peaking at 251 days in September 2025. This trajectory suggests a substantial accumulation of stock or a decline in sales velocity, representing the primary driver of the overall increase in the cash conversion cycle.
Average Receivable Collection Period
The collection of receivables shows a general upward trend characterized by moderate volatility. From a baseline of 52 to 59 days in early 2022, the period expanded to reach 87 days by September 2024. Although subsequent fluctuations occurred between 66 and 83 days, the general trend indicates that cash is being recovered from customers more slowly compared to the initial periods of analysis.
Average Payables Payment Period
A strategic extension in the payment of obligations to suppliers is evident. The period increased from 55 days in April 2022 to a high of 119 days in December 2025. This upward trend suggests a reliance on supplier financing to conserve cash and partially offset the liquidity pressures created by the lengthening inventory and receivable periods.
Cash Conversion Cycle Synthesis
The net impact of these movements is a substantial deterioration in the operating cycle. The expansion of the inventory processing period far outweighed the mitigating effects of the delayed payables payments. As a result, the duration required to convert investments in inventory and receivables back into cash has significantly lengthened, ending the period at 207 days in March 2026.

AI Ask an analyst for more